Vaxcyte, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Olivier Brandicourt, M.D.

Vaxcyte, Inc.’s own tally for this item (“Elect Director: Olivier Brandicourt, M.D.”): 116,370,183 for, 16,643,897 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 67,002,205 for, 2,323,684 withheld, 1,104,841 abstained.

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

Description as filed by funds: Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Halley Gilbert, J.D.

Vaxcyte, Inc.’s own tally for this item (“Elect Director: Halley Gilbert, J.D.”): 114,704,274 for, 18,309,806 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 66,704,694 for, 2,621,194 withheld, 1,104,842 abstained.

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

Description as filed by funds: Election of Class III Directors Nominees would serve until the 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Grant E. Pickering, M.B.A.

Vaxcyte, Inc.’s own tally for this item (“Elect Director: Grant Pickering, M.B.A.”): 132,112,840 for, 901,240 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 70,113,523 for, 237,590 withheld, 79,617 abstained.

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

Description as filed by funds: Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.

Vaxcyte, Inc.’s own tally for this item (“3. The approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers”): 130,011,017 for, 2,755,868 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The approval of the non-binding resolution on named executive officer compensation was approved by the votes indicated:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Vaxcyte, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “SAY ON PAY” (2 managers, 54 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 92 managers: 69,300,959 for, 1,128,836 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 284 managers: 115,774,316 for, 2,180,765 against, 1,975,153 withheld, 3,840 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Vaxcyte, Inc.’s own tally for this item (“2. The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 137,230,032 for, 137,589 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The appointment was ratified by the votes indicated:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 70,430,834 for, 66 against.

Showing the 25 largest of 94 asset managers. See all 94 in the interactive database.